Newsletters

	IFPA Quarterly - December 2019 Learn about the past year and everything we are looking forward to in 2020.
	IFPA Quarterly - January 2019 Learn what IFPA has planned for 2019.

World Psoriasis Day Reports

	WPD 2019 - Report A preliminary report on the events of World Psoriasis Day 2019 to celebrate the theme "CONNECTED"
	WPD 2018 - Report A preliminary report on the events of World Psoriasis Day 2018 on the theme of "Treat Psoriasis Seriously"
	WPD 2016 - Report A comprehensive report on all activities our national members held around World Psoriasis Day 2016.
	WPD 2016 - General Summary An overview of World Psoriasis Day 2016: the annual theme, samples of our members’ activities and photos of the events.
	WPD 2015 - Report A comprehensive report on all activities our national members held around World Psoriasis Day 2015.
	WPD 2015 - General Summary An overview of World Psoriasis Day 2015: the annual theme, samples of our members’ activities and photos of the events.
	WPD 2014 - General Summary An overview of World Psoriasis Day 2014: the annual theme, samples of our members’ activities and photos of the events.
	WPD 2013 - Report A comprehensive report on all activities our national members held around World Psoriasis Day 2013.
	WPD 2013 - General Summary An overview of World Psoriasis Day 2013: the annual theme, samples of our members’ activities and photos of the events.

IFPA World Conference Programmes

	IFPA World Conference 2015 Read more about the World Conference.
	IFPA World Conference 2015 Read more about the World Conference.
	IFPA World Conference 2012 Read more about the World Conference.
	IFPA World Conference 2009 Read more about the World Conference.
	IFPA World Conference 2006 Read more about the World Conference.

Information Material

	IFPA Position Paper: Biosimilars IFPA's official statement regarding the safety and efficacy of biosimilars.
	Advocacy Toolkit for Universal Health Coverage Let this guide inspire you to use Universal Health Coverage to campaign for psoriasis and psoriatic arthritis
	NCDA IFPA Psoriasis Comorbidities Brief English version Read about the joint policy brief of IFPA and NCD Alliance.
	NCDA IFPA Psoriasis Comorbidities Brief French version Read about the joint policy brief of IFPA and NCD Alliance.
	NCDA IFPA Psoriasis Comorbidities Brief Spanish version Read about the joint policy brief of IFPA and NCD Alliance.
	NCDA IFPA Psoriasis Comorbidities Brief Portuguese version Read about the joint policy brief of IFPA and NCD Alliance.
	IFPA Infographic 1 An infographic illustrating the burden of psoriasis – physically, socioeconomically and psychosocially.
	IFPA Infographic 2 An infographic illustrating the latest psoriasis advocacy developments, with practical recommended actions on addressing unmet needs.
	Issue Brief on Psoriasis While psoriasis can be disabling, this issue brief shows that it does not need to be a barrier to full participation in society.
	Issue Brief on Psoriatic Arthritis An introductory issue brief on psoriatic arthritis, which explains why the disease is a serious issue and ends with a call for action.
	Brochure on Psoriasis This general brochure on psoriasis discusses the disease’s definition, treatment examples, burden, etc. The brochure is advocacy-focused and includes a practicall call for action.

Financial Reports

IFPA Financial Report 2013-2015 Our latest financial reports – from 2013 to 2015.

World Health Organization documents

	WHO Global Report on Psoriasis The World Health Organization’s first-ever comprehensive report on psoriasis, published in 2016.
	WHO Resolution on Psoriasis The World Health Organization’s first-ever Resolution (WHA67.9) on Psoriasis, approved by WHO member states in 2014.

Activity Reports

	IFPA Activity Report 2015 Read more about our annual activities and events during 2015.
	IFPA Activity Report 2014 Read more about our annual activities and events during 2014.
	IFPA Activity Report 2013 Read more about our annual activities and events during 2013.

Miscellaneous

Code of Practice on Relationships With The Pharmaceutical Industry We believe in transparency. That’s why we adhere to this strict Code of Practice when engaging with corporate partners from the pharmaceutical industry.